These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35262074)

  • 1. Venezuelan Equine Encephalitis Virus V3526 Vaccine RNA-Dependent RNA Polymerase Mutants Increase Vaccine Safety Through Restricted Tissue Tropism in a Murine Model.
    Haines CA; Campos RK; Azar SR; Warmbrod KL; Kautz TF; Forrester NL; Rossi SL
    Zoonoses (Burlingt); 2022; 2():. PubMed ID: 35262074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-fidelity Venezuelan equine encephalitis virus polymerase mutants to improve live-attenuated vaccine safety and efficacy.
    Kautz TF; Guerbois M; Khanipov K; Patterson EI; Langsjoen RM; Yun R; Warmbrod KL; Fofanov Y; Weaver SC; Forrester NL
    Virus Evol; 2018 Jan; 4(1):vey004. PubMed ID: 29593882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses.
    Fine DL; Roberts BA; Teehee ML; Terpening SJ; Kelly CL; Raetz JL; Baker DC; Powers AM; Bowen RA
    Vaccine; 2007 Feb; 25(10):1868-76. PubMed ID: 17240002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection of hamsters by Venezuelan equine encephalitis virus candidate vaccine V3526 against lethal challenge by mosquito bite and intraperitoneal injection.
    Turell MJ; Parker MD
    Am J Trop Med Hyg; 2008 Feb; 78(2):328-32. PubMed ID: 18256440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurovirulence evaluation of Venezuelan equine encephalitis (VEE) vaccine candidate V3526 in nonhuman primates.
    Fine DL; Roberts BA; Terpening SJ; Mott J; Vasconcelos D; House RV
    Vaccine; 2008 Jun; 26(27-28):3497-506. PubMed ID: 18508163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1,5-Iodonaphthyl azide-inactivated V3526 protects against aerosol challenge with virulent venezuelan equine encephalitis virus.
    Gupta P; Sharma A; Spurgers KB; Bakken RR; Eccleston LT; Cohen JW; Honnold SP; Glass PJ; Maheshwari RK
    Vaccine; 2016 May; 34(25):2762-5. PubMed ID: 27129427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate.
    Hart MK; Caswell-Stephan K; Bakken R; Tammariello R; Pratt W; Davis N; Johnston RE; Smith J; Steele K
    Vaccine; 2000 Jul; 18(26):3067-75. PubMed ID: 10825611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative neurovirulence of attenuated and non-attenuated strains of Venezuelan equine encephalitis virus in mice.
    Ludwig GV; Turell MJ; Vogel P; Kondig JP; Kell WK; Smith JF; Pratt WD
    Am J Trop Med Hyg; 2001; 64(1-2):49-55. PubMed ID: 11425162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel DNA-launched Venezuelan equine encephalitis virus vaccine with rearranged genome.
    Tretyakova I; Tibbens A; Jokinen JD; Johnson DM; Lukashevich IS; Pushko P
    Vaccine; 2019 May; 37(25):3317-3325. PubMed ID: 31072736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-Amplifying RNA Vaccines for Venezuelan Equine Encephalitis Virus Induce Robust Protective Immunogenicity in Mice.
    Samsa MM; Dupuy LC; Beard CW; Six CM; Schmaljohn CS; Mason PW; Geall AJ; Ulmer JB; Yu D
    Mol Ther; 2019 Apr; 27(4):850-865. PubMed ID: 30770173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venezuelan equine encephalitis vaccine with rearranged genome resists reversion and protects non-human primates from viremia after aerosol challenge.
    Tretyakova I; Plante KS; Rossi SL; Lawrence WS; Peel JE; Gudjohnsen S; Wang E; Mirchandani D; Tibbens A; Lamichhane TN; Lukashevich IS; Comer JE; Weaver SC; Pushko P
    Vaccine; 2020 Apr; 38(17):3378-3386. PubMed ID: 32085953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetically engineered, live, attenuated vaccines protect nonhuman primates against aerosol challenge with a virulent IE strain of Venezuelan equine encephalitis virus.
    Reed DS; Lind CM; Lackemeyer MG; Sullivan LJ; Pratt WD; Parker MD
    Vaccine; 2005 May; 23(24):3139-47. PubMed ID: 15837213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Environmental hazard assessment of Venezuelan equine encephalitis virus vaccine candidate strain V3526.
    Rao V; Hinz ME; Roberts BA; Fine D
    Vaccine; 2004 Jun; 22(20):2667-73. PubMed ID: 15193393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative neurovirulence and tissue tropism of wild-type and attenuated strains of Venezuelan equine encephalitis virus administered by aerosol in C3H/HeN and BALB/c mice.
    Steele KE; Davis KJ; Stephan K; Kell W; Vogel P; Hart MK
    Vet Pathol; 1998 Sep; 35(5):386-97. PubMed ID: 9754544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus.
    Martin SS; Bakken RR; Lind CM; Garcia P; Jenkins E; Glass PJ; Parker MD; Hart MK; Fine DL
    Vaccine; 2010 Apr; 28(18):3143-51. PubMed ID: 20193792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models.
    Pratt WD; Davis NL; Johnston RE; Smith JF
    Vaccine; 2003 Sep; 21(25-26):3854-62. PubMed ID: 12922119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multisystem approach for development and evaluation of inactivated vaccines for Venezuelan equine encephalitis virus (VEEV).
    Fine DL; Jenkins E; Martin SS; Glass P; Parker MD; Grimm B
    J Virol Methods; 2010 Feb; 163(2):424-32. PubMed ID: 19903494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB.
    Martin SS; Bakken RR; Lind CM; Garcia P; Jenkins E; Glass PJ; Parker MD; Hart MK; Fine DL
    Vaccine; 2010 Jan; 28(4):1031-40. PubMed ID: 19914193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability of RNA virus attenuation approaches.
    Kenney JL; Volk SM; Pandya J; Wang E; Liang X; Weaver SC
    Vaccine; 2011 Mar; 29(12):2230-4. PubMed ID: 21288800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ablation of Programmed -1 Ribosomal Frameshifting in Venezuelan Equine Encephalitis Virus Results in Attenuated Neuropathogenicity.
    Kendra JA; de la Fuente C; Brahms A; Woodson C; Bell TM; Chen B; Khan YA; Jacobs JL; Kehn-Hall K; Dinman JD
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27852852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.